Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AstraZeneca PLC (GB:AZN)
LSE:AZN
Earnings Data
Report Date
Apr 29, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
174.85Last Year’s EPS
162.76Same Quarter Last Year
Moderate Buy
Based on 13 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 06, 2025
|% Change Since: 5.69%
|Next Earnings Date:Apr 29, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a strong performance over the past year with significant financial growth and pipeline advancements. However, challenges in China and anticipated impacts from IRA and VBP present headwinds. The company remains optimistic about its growth strategy and future opportunities.Company Guidance
The call provided comprehensive guidance on the company's performance and future outlook, highlighting several key metrics. In 2024, the company achieved a 21% increase in total revenue and a 19% rise in core EPS, while maintaining a 14% growth in core operating expenses. The company conducted nine pivotal trial readouts, representing over $5 billion in non-risk adjusted peak year revenue. For 2025, the guidance anticipates a high single-digit percentage increase in total revenue and a low double-digit percentage rise in core EPS. The core product sales gross margin is expected to decline by 70 basis points due to factors like the IRA in the U.S. and VBP inclusion in China. The company plans to increase CapEx by 50% in 2025, driven by investments in manufacturing and technology. Additionally, the full-year dividend is projected to increase to $3.20 per share. The company continues to focus on growth in emerging markets, with overall emerging market growth at 22% in 2024.Strong Financial Performance in 2024
Total revenue increased by 21% and core EPS grew by 19%, illustrating strong underlying momentum. Core operating expenses grew by 14%, showing leverage with lower growth relative to total revenue.
Pipeline Advancements
Nine high-value pivotal trials readouts were delivered, representing over $5 billion in non-risk adjusted peak year revenue. Eight new medicines were approved, including Datroway.
Emerging Markets Growth
Emerging market growth was at 22% in 2024, with non-China emerging markets growing by 32%.
Oncology Segment Success
Oncology delivered total revenues of $22.4 billion, a 24% increase, with key medicines achieving significant milestones. Tagrisso achieved over $6.5 billion, and Calquence grew by 20%.
BioPharmaceuticals Growth
BioPharmaceuticals medicine saw revenue growing 21% to $21.9 billion in 2024, with strong growth in R&I (28%) and CVRM (17%).
Rare Disease Segment Growth
Rare disease delivered total revenue of $8.8 billion in 2024, up 16% year-over-year, driven by increased patient demand and new market launches.
---
GB:AZN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GB:AZN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 06, 2025 | 10966.30p | 11616.82p | +5.93% |
| Nov 12, 2024 | 9841.68p | 9846.60p | +0.05% |
| Jul 25, 2024 | 11965.06p | 11814.20p | -1.26% |
| Apr 25, 2024 | 11120.63p | 11780.89p | +5.94% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does AstraZeneca PLC (GB:AZN) report earnings?
AstraZeneca PLC (GB:AZN) is schdueled to report earning on Apr 29, 2025, TBA Not Confirmed.
What is AstraZeneca PLC (GB:AZN) earnings time?
AstraZeneca PLC (GB:AZN) earnings time is at Apr 29, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of AstraZeneca PLC stock?
The P/E ratio of AstraZeneca is N/A.
What is GB:AZN EPS forecast?
GB:AZN EPS forecast for the fiscal quarter 2025 (Q1) is 174.85.
---